Spirepoint Private Client Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 | +$13.4M | |
| 2 | +$10.4M | |
| 3 | +$9.29M | |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$8.41M |
| 5 |
Chubb
CB
|
+$6.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 | +$7.95M | |
| 2 | +$5.38M | |
| 3 | +$4.88M | |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$4.53M |
| 5 |
Ares Management
ARES
|
+$3.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.75% |
| 2 | Industrials | 17.92% |
| 3 | Financials | 7.19% |
| 4 | Consumer Discretionary | 6.94% |
| 5 | Healthcare | 6.38% |
Similar funds
Spirepoint Private Client's Q2 2026 Portfolio in Review
As of Q2 2026, Spirepoint Private Client held 347 positions worth $1.23B, up 17% from $1.05B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Spirepoint Private Client deployed $67.1M of net new capital in Q2 2026, opening 25 new positions and adding to 132 existing holdings. Its largest new stake was iShares Semiconductor ETF: 26,384 shares worth $16.9M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 22% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $7.95M trimmed.
- Spirepoint Private Client's largest Q2 2026 buy was iShares Semiconductor ETF: 26,384 shares worth $16.9M.
- Spirepoint Private Client added most to Arista Networks in Q2 2026, an estimated $10.4M increase.
- Spirepoint Private Client's biggest Q2 2026 reduction was Thermo Fisher Scientific, cutting an estimated $7.95M.
- Spirepoint Private Client fully exited Ares Management in Q2 2026, selling an estimated $3.97M.
- Spirepoint Private Client's ten largest holdings make up 36% of its $1.23B portfolio in Q2 2026.
- Spirepoint Private Client opened 25 new positions and closed 15 in Q2 2026.
- Spirepoint Private Client's portfolio value rose 17% quarter-over-quarter to $1.23B.
Based on Spirepoint Private Client's 13F filing for Q2 2026, filed 5 Aug 2026.